Timothy Rodell Jr, CEO of GlobeImmune Inc, bought 5,000 shares of GlobeImmune Inc (Stock Symbol: GBIM) at $10 per share for a total amount of $50 thousand on July 8, 2014.
GlobeImmune Inc is headquartered in Louisville, CO.
On July 8, 2014, GlobeImmune Inc announced the closing of its previously announced initial public offering of 1,725,000 shares of its common stock at a price to the public of $10.00 per share, which includes 225,000 shares of common stock sold pursuant to the full exercise of the underwriter’s overallotment option. The gross proceeds to GlobeImmune from the initial public offering were $17,250,000, before deducting underwriting discounts and commissions and other offering expenses. Shares of GlobeImmune, Inc. trade on the NASDAQ Capital Market under the ticker symbol “GBIM.”
According to Capital IQ, GlobeImmune Inc has a market cap of 60.98 million, an enterprise value of 56.05 million, and trailing 12 month revenues of N/A.
GlobeImmune Inc. operates as a biopharmaceutical company. The company develops and manufactures Tarmogens, a molecular immunotherapy vaccine for the treatment of cancer and infectious diseases. Its products include GI-4000 for pancreas, non-small cell lung, colorectal, endometrial, and ovarian cancers, as well as melanoma and multiple myeloma; GI-6207 for the treatment of human epithelial cancers, including non-small cell lung cancer, colorectal, pancreas, breast, gastric, and medullary thyroid cancers; GI-6301, a Tarmogen used for the treatment of lung, breast, colon, bladder, kidney, ovary, uterus, and prostate cancers; and GS-4774 a therapeutic vaccine for chronic HBV infection. GlobeImmune, Inc. was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune Inc. in 2001. The company was founded in 1995 and is based in Louisville, Colorado.
Timothy Rodell Jr’s most recent annual compensation from GlobeImmune Inc is a salary of $388,125, $54 in other compensation, and a total compensation of $388,179.
According to his biography, Dr. Timothy C. Rodell, M.D., is President, Chief Executive Officer, Director of GlobeImmune Inc. He has been Chief Executive Officer and has served as a member of Board of Directors since April 2003 and he has been President since June 2005. From March 2002 until April 2003, Dr. Rodell worked with SMG, Inc., a pharmaceutical consulting firm. From November 1999 until February 2002, Dr. Rodell was President and Chief Executive Officer of RxKinetix, Inc., a private drug delivery company. From March 1996 until October 2000, he held a number of positions at OXIS International, Inc., a publicly-traded developer of biotech and pharmaceutical technologies and products, including Chief Technology Officer and Chairman and President of OXIS International, SA, the company’s French subsidiary. From 1985 until 1995, Dr. Rodell was at Cortech, Inc., a publicly-traded biopharmaceutical company, where he was most recently Executive Vice President of Operations and Product Development. He currently serves on the board of directors of the Biotechnology Industry Organization. Dr. Rodell earned his M.D. from the University of North Carolina School of Medicine and is board certified in internal medicine and pulmonary medicine.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.